Miracle Grow For Tumors?
Executive Summary
Amgen and FDA debated the science behind the potential for erythropoiesis-stimulating agents to stimulate tumor growth at the expense of committee discussion during the May 10 meeting of FDA's Oncologic Drugs Advisory Committee. During the sponsor question and answer period, temporary member Silvana Martino asked for information related to the mechanism of action by which ESAs could potentially accelerate tumor progression: